PURPOSE: We investigated in a single institution series of 124 women with operable breast cancer whether tumor clinicopathological features could predict the 70-gene signature (Mammaprint, MP) results, and whether MP results could help to make decisions for the use of chemotherapy (CT) in patients (pts) with ER positive breast cancer beyond recommendations of international guidelines. RESULTS: Among the 68 ER/PgR positive, HER2 negative tumors, Ki-67 ≥ 20% was the only significant predictor of a high risk-MP among standard clinicopathological features. In candidates for endocrine therapy with undetermined benefit from CT according to international guidelines, MP results would have led to different treatment decisions in 13/46 (28%) and in 20/68 (29%) pts according to NCCN and St. Gallen recommendations, respectively. CONCLUSIONS: Ki-67 independently predicted high risk-MP in ER/PgR positive, HER2 negative tumors. MP results would have led to discordant treatment recommendations in about 30% of cases, generally increasing indication rate for CT. The results of large randomized trials are warranted in order to understand whether we should rely on multigene assays rather than on standard clinicopathological features for treatment decisions.
PURPOSE: We investigated in a single institution series of 124 women with operable breast cancer whether tumor clinicopathological features could predict the 70-gene signature (Mammaprint, MP) results, and whether MP results could help to make decisions for the use of chemotherapy (CT) in patients (pts) with ER positive breast cancer beyond recommendations of international guidelines. RESULTS: Among the 68 ER/PgR positive, HER2 negative tumors, Ki-67 ≥ 20% was the only significant predictor of a high risk-MP among standard clinicopathological features. In candidates for endocrine therapy with undetermined benefit from CT according to international guidelines, MP results would have led to different treatment decisions in 13/46 (28%) and in 20/68 (29%) pts according to NCCN and St. Gallen recommendations, respectively. CONCLUSIONS: Ki-67 independently predicted high risk-MP in ER/PgR positive, HER2 negative tumors. MP results would have led to discordant treatment recommendations in about 30% of cases, generally increasing indication rate for CT. The results of large randomized trials are warranted in order to understand whether we should rely on multigene assays rather than on standard clinicopathological features for treatment decisions.
Authors: Kristian Jensen; Rikke Krusenstjerna-Hafstrøm; Jesper Lohse; Kenneth H Petersen; Helene Derand Journal: Mod Pathol Date: 2016-10-21 Impact factor: 7.842
Authors: Hyun Ae Jung; Yeon Hee Park; Moonjin Kim; Sungmin Kim; Won Jin Chang; Moon Ki Choi; Jung Yong Hong; Seok Won Kim; Won Ho Kil; Jeong Eon Lee; Seok Jin Nam; Jin Seok Ahn; Young-Hyuck Im Journal: Tumour Biol Date: 2014-10-19
Authors: Theresa Westphal; Simon P Gampenrieder; Gabriel Rinnerthaler; Marija Balic; Florian Posch; Nadia Dandachi; Cornelia Hauser-Kronberger; Roland Reitsamer; Karl Sotlar; Bianca Radl; Christoph Suppan; Herbert Stöger; Richard Greil Journal: Breast Care (Basel) Date: 2021-03-30 Impact factor: 2.860
Authors: Jeanette K Birnbaum; Foluso O Ademuyiwa; Josh J Carlson; Leslie Mallinger; Mark W Mason; Ruth Etzioni Journal: Med Decis Making Date: 2015-08-24 Impact factor: 2.583
Authors: A Kuijer; A C M van Bommel; C A Drukker; M van der Heiden-van der Loo; C H Smorenburg; P J Westenend; S C Linn; E J Th Rutgers; S G Elias; Th van Dalen Journal: Genet Med Date: 2015-11-19 Impact factor: 8.822